8F8 Stock Chart & Stats
€2.08
€0.06(6.50%)
At close: 4:00 PM EST
€2.08
€0.06(6.50%)
Day’s Range― - ―
52-Week Range€0.97 - €2.32
Previous CloseN/A
Volume0.00
Average Volume (3M)89.00
Market Cap
€91.46M
Enterprise Value€1.17K
Total Cash (Recent Filing)€14.23M
Total Debt (Recent Filing)€929.00K
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding53,330,242
10 Day Avg. Volume268
30 Day Avg. Volume89
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageExtremely low leverage and a substantial equity base provide financial flexibility compared with highly indebted peers. This reduces near-term debt-servicing pressure while SynAct advances its clinical pipeline, although ongoing cash burn remains a constraint.
Focused Therapeutic PlatformA differentiated resolution-of-inflammation approach could support multiple autoimmune and inflammatory indications if clinical efficacy is demonstrated. The platform focus may create longer-term pipeline leverage beyond a single narrowly defined product.
Losses Improved From 2023The reduction in losses from the 2023 level indicates some progress in limiting the scale of annual financial losses. If sustained through disciplined spending and development execution, this could extend the company’s runway before commercial revenues emerge.
Bears Say
No Commercial RevenueWithout commercial revenue, SynAct has no operating sales base to fund research, development, or corporate costs. The business therefore remains dependent on successful clinical progress, partnerships, licensing, or future capital raising.
Sustained Cash BurnPersistent negative operating and free cash flow indicates that the current business does not self-fund. Continued development spending may require external financing, creating funding dependency and potential dilution before products generate revenue.
Uneven Loss TrajectoryThe uneven loss trajectory suggests cost control has not produced a consistently improving earnings profile. Continued heavy EBIT and net losses could consume equity and constrain strategic flexibility while clinical programs remain pre-commercial.
SynAct Pharma AB News
8F8 FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was €0.97 and its highest was €2.32 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is €91.46M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Nov 03, 2026 which is in 67 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Aug 20, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 53,330,242 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -€0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.574%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in DE:8F8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
InDex Pharmaceuticals Holding AB
―
Active Biotech AB
―
Cantargia AB
―